ArticleScientific reports2026
Comparative effects of intranasal and intraperitoneal resveratrol on the eye-brain axis in a cisplatin-induced neurotoxic rat model.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cisplatin (CISP) is a platinum-based chemotherapeutic drugs that are commonly used to treat several types of cancers. However, its clinical application faces several hurdles that could limit its clinical efficiency such as central and retinal neurotoxicity. Hence, it is crucial to develop antioxidant-based co-therapeutic approaches to mitigate CISP-induced neurotoxicity. Resveratrol (RSV) is a naturally occurring polyphenol that exhibits a plethora of health-promoting activities. The present study aimed to compare the neuroprotective impact of intranasal (IN) and intraperitoneal (IP) doses of RSV on the alleviation of CISP-induced neurotoxicity. Rats were allocated into four groups: Negative control, CISP-rats, treated CISP-rats with IN RSV, and treated CISP-rats with IP RSV. Assessment of lipid peroxides and catalase activities in the brain and ocular tissues were conducted. The brain acetylcholinesterase (AChE) activity and the eye 8-Hydroxy-2-deoxyguanosine (8-OHdG) content were estimated. Furthermore, the gene expression of interleukin-10 (IL-10) and caspase-8 was performed. In addition, serum nuclear factor erythroid 2-related factor 2 (Nrf2) level, as well as the extent of DNA damage in blood cells were evaluated. Histopathological analyses of different regions of the brain and the eye tissues were conducted. Our findings demonstrated that both IN and IP doses of RSV mitigated the central and retinal toxicity as demonstrated biochemically and histopathologically; indicating the anti-oxidant, anti-inflammatory, genoprotective, and anti-apoptotic activities of RSV. Collectively, IP RSV exhibited a superior cumulative neuroprotective activity than IN RSV. However, IN administration of RSV could be regarded as a simple and alternative non-invasive therapeutic approach for receiving RSV with further improvements.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.